RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
OncoTherapy Science Stock

OncoTherapy Science Net Income 2024

OncoTherapy Science Net Income

-1.29 B JPY

Ticker

4564.T

ISIN

JP3202150003

WKN

726692

In 2024, OncoTherapy Science's profit amounted to -1.29 B JPY, a 15.15% increase from the -1.12 B JPY profit recorded in the previous year.

The OncoTherapy Science Net Income history

YEARNET INCOME (undefined JPY)
2024-
2023-
2022-
2021-
2020-
2019-
2018-
2017-
2016-
2015-
2014-
2013-
2012-
2011-
2010-
2009-
2008-
2007-
2006-
2005-

OncoTherapy Science Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into OncoTherapy Science, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by OncoTherapy Science from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects OncoTherapy Science’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of OncoTherapy Science. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into OncoTherapy Science’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing OncoTherapy Science’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on OncoTherapy Science’s growth potential.

OncoTherapy Science Revenue, EBIT and net profit per share

DateOncoTherapy Science RevenueOncoTherapy Science EBITOncoTherapy Science Net Income
20240 undefined0 undefined0 undefined
20230 undefined0 undefined0 undefined
20220 undefined0 undefined0 undefined
20210 undefined0 undefined0 undefined
20200 undefined0 undefined0 undefined
20190 undefined0 undefined0 undefined
20180 undefined0 undefined0 undefined
20170 undefined0 undefined0 undefined
20160 undefined0 undefined0 undefined
20150 undefined0 undefined0 undefined
20140 undefined0 undefined0 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined
20100 undefined0 undefined0 undefined
20090 undefined0 undefined0 undefined
20080 undefined0 undefined0 undefined
20070 undefined0 undefined0 undefined
20060 undefined0 undefined0 undefined
20050 undefined0 undefined0 undefined

OncoTherapy Science stock margins

The OncoTherapy Science margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OncoTherapy Science. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OncoTherapy Science.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the OncoTherapy Science's sales revenue. A higher gross margin percentage indicates that the OncoTherapy Science retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the OncoTherapy Science's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the OncoTherapy Science's total revenue generated. When comparing the revenue margin year over year, investors can gauge the OncoTherapy Science's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the OncoTherapy Science. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the OncoTherapy Science's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

OncoTherapy Science Margin History

OncoTherapy Science Gross marginOncoTherapy Science Profit marginOncoTherapy Science EBIT marginOncoTherapy Science Profit margin
20240 %0 %0 %
20230 %0 %0 %
20220 %0 %0 %
20210 %0 %0 %
20200 %0 %0 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %
20160 %0 %0 %
20150 %0 %0 %
20140 %0 %0 %
20130 %0 %0 %
20120 %0 %0 %
20110 %0 %0 %
20100 %0 %0 %
20090 %0 %0 %
20080 %0 %0 %
20070 %0 %0 %
20060 %0 %0 %
20050 %0 %0 %

OncoTherapy Science Aktienanalyse

What does OncoTherapy Science do?

OncoTherapy Science Inc is a rising company that focuses on the research and development of novel cancer therapies. The company takes pride in being able to combine the latest scientific findings with cutting-edge technologies to develop highly effective drugs and therapies that can improve the lives of cancer patients. The company is based in Japan and was founded in 2001. Since its inception, it has become one of the leading companies in cancer research and its products are available worldwide. OncoTherapy Science Inc's business model is based on the development and commercialization of new innovative cancer therapies. The company utilizes the latest technologies and research findings to achieve groundbreaking advancements in cancer treatment. These innovative therapies have the potential to improve the survival and quality of life of cancer patients. OncoTherapy Science Inc divides its activities into various areas. This includes the research and development of drugs, the clinical testing of new therapies, and the production and commercialization of cancer therapies. The research and development of new drugs form the core of OncoTherapy Science Inc's activities. The company continuously invests in researching new treatment approaches to improve the effectiveness and safety of cancer therapies. Advanced technologies such as genome sequencing and molecular diagnostics are utilized to develop personalized therapies tailored to specific types of cancer and patients. OncoTherapy Science Inc also conducts extensive clinical trials to evaluate the effectiveness and safety of its therapies. The success rate of clinical studies is very high, and many of the therapies have already received approval from regulatory authorities. Another important area of OncoTherapy Science Inc is the production and commercialization of cancer therapies. The company works closely with its distribution partners to ensure that its products are available in many countries and regions. OncoTherapy Science Inc's therapies are recommended by many oncologists and used in leading clinical institutions worldwide. Products of OncoTherapy Science Inc include a range of innovative cancer therapies. These include antibody-based drugs, immunotherapies, RNA-based therapies, and chemotherapy. These therapies have the potential to improve the effectiveness of cancer treatment and enhance the quality of life of cancer patients. An example of an innovative therapy by OncoTherapy Science Inc is OTS964, a new chemotherapeutic agent for the treatment of pancreatic cancer and other cancers. OTS964 inhibits the enzyme TOPK, which is overexpressed in many types of cancer, leading to the death of cancer cells. This therapy has shown promising results in animal models and is currently being tested in clinical trials. OncoTherapy Science Inc aims to contribute to improving the quality of life of cancer patients. The company relies on a combination of innovative research, state-of-the-art technology, and close collaboration with other industry stakeholders to achieve a leading position in cancer research. With its strong market position and commitment to cancer research, OncoTherapy Science Inc is a company that will achieve much in the future. OncoTherapy Science ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Net Income Details

Understanding OncoTherapy Science's Profit Margins

The profit margins of OncoTherapy Science represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of OncoTherapy Science's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.

Year-to-Year Comparison

Evaluating OncoTherapy Science's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.

Impact on Investments

OncoTherapy Science's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.

Interpreting Profit Fluctuations

When OncoTherapy Science’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.

Frequently Asked Questions about OncoTherapy Science stock

How much profit has OncoTherapy Science made this year?

OncoTherapy Science has made -1.29 B JPY this year.

How has the profit developed compared to last year?

The profit has increased by 15.15% compared to last year increased

What impact do the earnings have on the shareholders?

An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.

How does OncoTherapy Science publish its earnings?

OncoTherapy Science publishes its earnings in the form of quarterly or annual reports.

Which financial indicators are included in the quarterly or annual reports?

The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.

Why is it important for investors to know the earnings of OncoTherapy Science?

The profits of OncoTherapy Science are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.

How can one learn more about the earnings of OncoTherapy Science?

You can learn more about the earnings of OncoTherapy Science by reviewing the quarterly or annual reports or following the company presentations.

How much dividend does OncoTherapy Science pay?

Over the past 12 months, OncoTherapy Science paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, OncoTherapy Science is expected to pay a dividend of 0 JPY.

What is the dividend yield of OncoTherapy Science?

The current dividend yield of OncoTherapy Science is .

When does OncoTherapy Science pay dividends?

OncoTherapy Science pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of OncoTherapy Science?

OncoTherapy Science paid dividends every year for the past 0 years.

What is the dividend of OncoTherapy Science?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is OncoTherapy Science located?

OncoTherapy Science is assigned to the 'Health' sector.

Wann musste ich die Aktien von OncoTherapy Science kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of OncoTherapy Science from 9/17/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/17/2024.

When did OncoTherapy Science pay the last dividend?

The last dividend was paid out on 9/17/2024.

What was the dividend of OncoTherapy Science in the year 2023?

In the year 2023, OncoTherapy Science distributed 0 JPY as dividends.

In which currency does OncoTherapy Science pay out the dividend?

The dividends of OncoTherapy Science are distributed in JPY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von OncoTherapy Science

Our stock analysis for OncoTherapy Science Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OncoTherapy Science Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.